Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: J Cancer Res Clin Oncol. 2014 Oct 17;141(4):615–626. doi: 10.1007/s00432-014-1855-4

Fig. 1.

Fig. 1

a Growth curves of single-agent MK-2206 in NSCLC cell lines. Cells were treated for 72 h prior to MTT. Legend is in order of sensitivity as indicated by IC50. Mutation status indicates the presence of an EGFR or KRAS mutation, with the specific substitution in parentheses; wt indicates no known abnormalities in either EGFR or KRAS. b Immunoblot of phospho-AKT (S473) following 3 h of treatment with MK-2206 at the indicated dose